|
Synonyms: CaCP-29 | Gohibic® | IFX-1
vilobelimab is an approved drug
Compound class:
Antibody
Comment: Vilobelimab (IFX-1) is a chimeric IgG4 monoclonal antibody against the terminal complement component, anaphylatoxin C5a. It was developed for potential to treat complement mediated inflammatory diseases. Vilobelimab blocks C5a/C5aR1 signalling in subsets of myeloid-derived suppressor cells (MDSCs) and neutrophils.
|
| No information available. |
Summary of Clinical Use  |
| Vilobelimab (IFX-1) was advanced to clinical evaluation in difficult to treat inflammatory diseases [5-6,10]. SARS-CoV-2 and COVID-19: In response to the COVID-19 pandemic, vilobelimab was entered into clinical trial, with the purpose of determining potential efficacy of blocking the C5a-C5aR1 axis to limit myeloid infiltration and prevent excessive lung inflammation in COVID-19 patients [2], and early results were published which support progression to a higher powered Phase 3 study [13]. The EMA approved vilobelimab (Gohibic®) in January 2025, to treat COVID-19-associated acute respiratory distress syndrome. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03487276 | Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) | Phase 2 Interventional | InflaRx GmbH | 13 | |
| NCT03895801 | Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. | Phase 2 Interventional | InflaRx GmbH | 13 | |
| NCT03001622 | Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa | Phase 2 Interventional | InflaRx GmbH | 3 | |
| NCT04333420 | Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia | Phase 2/Phase 3 Interventional | InflaRx GmbH | 9,12-13 | |
| NCT05964413 | Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum | Phase 3 Interventional | InflaRx GmbH | ||
